Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 310

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 310
---
  December 31, 2024                                    83,844,411      390,979      ( 336,893)      27                  ( 49,471)                            8,834  

F-11

NOTES TO FINANCIAL STATEMENTS

Note 1: The company

Innate Pharma S. A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three

From its inception, the Company has incurred losses due to its research and development (“ R& D”) activity. The financial year ended December 31, 2024 generated a € 49,471 8,834

The Company’s future operations are highly dependent on a combination of factors, including: (i) the success of its R& D; (ii) regulatory approval and market acceptance of the Company’s future drug candidates; (iii) the timely and successful completion of additional financing; and (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies. As a result, the Company is and should continue, in the short to mid-term, to be financed through partnership agreements for the development and commercialization of its drug candidates and through the issuance of new equity instruments.

The Company’s activity is not subject to seasonal fluctuations.

As of December 31, 2024, the Company had one

This subsidiary is fully consolidated.

1.1. Significant contracts

The following paragraphs describe the key provisions of significant contracts.

a)Agreements related to monalizumab with Novo Nordisk A/S and with AstraZeneca

2014 Novo Nordisk A/S monalizumab agreement

On February 5, 2014, the Company acquired from Novo Nordisk A/S full development and commercialization rights to monalizumab. Novo Nordisk A/S received € 2.0 600,000 8.33 5.0 20.0 6.5

F-12

(as described below), Novo Nordisk A/S became entitled to a second and final additional payment amounting to $ 15.0 13.1 no 7.0

The net book value of the license amounted to € 0

Refer to Notes 2. h, 2. j and 6 for accounting description.

2015 AstraZeneca monalizumab agreements

Under co-development and option agreements signed with A